Lactate as an aid in sepsis diagnosis and management

Lactate and PCT are complementary markers to aid in the diagnosis and management of sepsis and septic shock.

Blood lactate in circulation can be used as a marker for systemic tissue hypoperfusion and it reflects cellular dysfunction in sepsis patients [1]. It is now included in the clinical criteria for septic shock defined in the Third International Consensus Definition for Sepsis and Septic Shock (Sepsis-3) [1].

Sepsis: Sepsis should be defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction can be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more [1].
Septic shock: Septic shock should be defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure (MAP) ≥ 65mmHg and lactate > 2 mmol/L (>18mg/dL) in the absence of hypovolemia [1].

PCT is typically the primary biomarker to aid in detection or rule-out of early sepsis

When measuring lactate in the ED setting the results are complementary to other test results, such as PCT for determination of level of bacterial or fungal infection, and together they serve as an important help in assessing the severity of the illness [3].

Lactate levels should be measured within 3 hours of admission and if elevated repeated within 6 hours, as recommended by the Surviving Sepsis Campaign guidelines [4].

This allows for the implementation and evaluation of effective hemodynamic management of the septic patient as early as possible, increasing the chances of survival [1, 3-5].
ss

Adapted from J-L Vincent, personal communications

Detecting sepsis

A simple infection can rapidly develop into sepsis a life-threatening condition which requires on-the-spot diagnosis and treatment while the condition is still in its early stages [1].

Diagnosing patients suspected of sepsis is both challenging and complex. Often patients arriving at the ED are febrile and have shortness of breath, low blood pressure, a high pulse and respiration - symptoms which can easily be confused with other severe conditions [3].

Early diagnosis and immediate treatment are crucial to increase the chances of surviving sepsis. The clinical evaluation alone is often insufficient for an early diagnosis of sepsis [5].

PCT and lactate are useful as aids in the diagnosis and management of sepsis, and complement the general clinical assessment of the patient’s physical condition [3].

What is lactate?

Lactate is a metabolite of glucose produced by tissues in the body under conditions of insufficient oxygen supply. Lactate is normally cleared by the liver and the kidneys, and the blood lactate concentration in unstressed patients is 1-1.5 mmol/L [6].

In critically ill patients, however, such as patients suffering a shock or hypoperfusion, lactate is often elevated to above 2 mmol/L, with lactate levels above 4 mmol/L indicating the need for immediate resuscitation and ICU admission [1, 6].

Elevated lactate levels indicate an imbalance and are associated with increased mortality in sepsis [5,6,7].

The value of measuring lactate in the diagnosis of sepsis

Patients with elevated lactate levels are seriously ill and require effective treatment here and now. Measuring lactate levels provides useful information about the progression of the condition and the effectiveness of the treatment [3].

For patients already suspected of sepsis, measuring the lactate levels provides useful information on the severity of the condition and enables monitoring of disease progression [3].

Find out more about cost-efficient lactate analysis or the role of PCT as an aid in the diagnosis of sepsis.

Visit acutecaretesting.org for more in-depth articles on diagnosing sepsis.

References

1. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315,8: 801-10
2. Vijayan AL, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of Intensive Care 2017
3. Freund Y et al. Serum lactate and procalcitonin measurements in emergency room for the diagnosis and risk-stratification of patients with suspected infection. Biomarkers 2012; 17 (7): 590-596
4. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign. International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637
5. Riedel S, et al. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 2011; 135:182-89
6. Seeger C et al. Acute care testing handbook. 2014
7. Andersen LW, et al. Etiology and therapeutic approach to elevated lactate. Mayo Clin Proc. 2013; 88(10): 1127-1140

Cookies are used on this website

Use of cookies

Don't show this message again

Radiometer is using Microsoft AZURE Active Directory to authenticate users

Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.

If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.

Key benefits

Allow the use of existing Active Directory credentials
Single-sign on experience
Use same credentials to access future services

Request access

You will receive an invitation to access our services via e-mail when your request has been approved.

When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.

Effective Date January 20th, 2023 (last updated January 20th, 2023)

ABOUT THIS POLICY

Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer,”, “our”, “us,” or “we”), collects, uses, shares, transfers and processes data collected from or about you.

“Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.

The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.

SCOPE

This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.

There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.